Global biopharmaceutical company AstraZeneca is strengthening focus on areas such as oncology, cardiovascular, renal, rare diseases, and the emerging GLP-1 segment. In September, it announced its third tranche of investment in the country over the past two years. Praveen Rao Akkinepally, Country President and Managing Director, AstraZeneca Pharma India, spoke exclusively to Business Today about the policy environment, the company’s priorities, and how India fits into its long-term global plans. Edited excerpts:
Q: How do you see AstraZeneca growing in India over the next three to five years?
A: At AstraZeneca, our mission is to push the boundaries of science to deliver life-changing medicines, and this mission guides everything we do. In India, we see a lot of unmet needs across disease areas that we are already addressing through our…